Biotech News

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Clearside Biomedical (CLSD)Clearside BiomedicalCompany update

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:

Related news

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

HROWHarrow, Inc.2026-09-30 11:00 EST

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

BLTEBelite Bio2026-09-29 00:00 EST

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

KPRXKiora Pharmaceuticals2026-10-29 11:00 EST

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

PRQRProQR Therapeutics2026-10-28 12:00 EST

ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

RHHBYRoche Holdings AG2026-09-30 05:00 EST

Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

HROWHarrow, Inc.2026-07-20 11:00 EST

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

IRIXIRIDEX2026-10-12 11:00 EST

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Clearside Biomedical

Clearside Biomedical is a drug-delivery and ophthalmology company focused on delivering therapies directly to the back of the eye. Its platform is built around improving how eye treatments reach retinal tissue.

Recent company news

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States